Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: <scp>ENHANCE‐M</scp> extension study2024 · 5 citations
2Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials2024 · 5 citations
3940-P: Efficacy and Safety of Enavogliflozin vs. Dapagliflozin as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Based on Renal Function—A Pooled Analysis of Two Randomized Controlled Trials2024
4Pharmacokinetics and Safety of Fixed‐Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects2025 · 1 citations
5Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes2025 · 2 citations

More from Diabetes Obesity and Metabolism

More from Seoul National University